Aura Biosciences Reports Officer/Director Changes & Compensatory Info

Ticker: AURA · Form: 8-K · Filed: 2025-04-02T00:00:00.000Z

Sentiment: neutral

Topics: officer-changes, director-changes, compensation

TL;DR

Aura Biosciences filed an 8-K detailing officer/director changes and compensation plans as of March 31, 2025.

AI Summary

Aura Biosciences, Inc. filed an 8-K on April 2, 2025, reporting events as of March 31, 2025. The filing primarily concerns the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial statements and exhibits.

Why It Matters

Changes in key personnel and executive compensation can signal shifts in company strategy or financial health, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in directors and officers, especially when coupled with compensatory arrangements, can indicate internal shifts that may affect the company's direction and stability.

Key Players & Entities

FAQ

What specific changes occurred regarding directors or officers?

The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers.

What is the date of the earliest event reported in this 8-K?

The date of the earliest event reported is March 31, 2025.

What is the company's principal executive office address?

The company's principal executive office is located at 80 Guest Street, Boston, Massachusetts, 02135.

What is the company's telephone number?

The company's telephone number, including area code, is 617 500-8864.

What other items are included in this filing besides personnel changes?

The filing also includes Financial Statements and Exhibits.

From the Filing

0000950170-25-048880.txt : 20250402 0000950170-25-048880.hdr.sgml : 20250402 20250402071511 ACCESSION NUMBER: 0000950170-25-048880 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250331 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250402 DATE AS OF CHANGE: 20250402 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aura Biosciences, Inc. CENTRAL INDEX KEY: 0001501796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 320271970 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40971 FILM NUMBER: 25802130 BUSINESS ADDRESS: STREET 1: 80 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 BUSINESS PHONE: (617)500-8864 MAIL ADDRESS: STREET 1: 80 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 8-K 1 aura-20250331.htm 8-K 8-K 0001501796 false 0001501796 2025-03-31 2025-03-31   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025     Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter)     Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)           80 Guest Street   Boston , Massachusetts   02135 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: 617 500-8864   Not Applicable (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.00001 par value per share   AURA   The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.   On March 31, 2025, the Board of Directors (the “Board”) of Aura Biosciences, Inc. (the “Company”) increased the size of the Board from six to seven directors and unanimously appointed Teresa Marie Bitetti, MBA, as a Class II director, effective March 31, 2025 (the “Effective Date”), to fill the newly created vacancy. Ms. Bitetti’s term will expire at the Company’s 2026 annual meeting of stockhold

View on Read The Filing